CA3107023A1 - Ep4 inhibitors and synthesis thereof - Google Patents

Ep4 inhibitors and synthesis thereof Download PDF

Info

Publication number
CA3107023A1
CA3107023A1 CA3107023A CA3107023A CA3107023A1 CA 3107023 A1 CA3107023 A1 CA 3107023A1 CA 3107023 A CA3107023 A CA 3107023A CA 3107023 A CA3107023 A CA 3107023A CA 3107023 A1 CA3107023 A1 CA 3107023A1
Authority
CA
Canada
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
cancer
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3107023A
Other languages
English (en)
French (fr)
Inventor
Mark Manfredi
Jeffrey Ecsedy
Alfredo C. Castro
Yoshiyuki Okumura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Askat Inc
Arrys Therapeutics Inc
Original Assignee
Askat Inc
Arrys Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Askat Inc, Arrys Therapeutics Inc filed Critical Askat Inc
Publication of CA3107023A1 publication Critical patent/CA3107023A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/52—Y being a hetero atom
    • C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
    • C07C311/63—N-sulfonylisoureas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA3107023A 2018-07-11 2019-07-11 Ep4 inhibitors and synthesis thereof Pending CA3107023A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862696440P 2018-07-11 2018-07-11
US62/696,440 2018-07-11
US201862737250P 2018-09-27 2018-09-27
US62/737,250 2018-09-27
US201962834525P 2019-04-16 2019-04-16
US62/834,525 2019-04-16
PCT/US2019/041351 WO2020014445A1 (en) 2018-07-11 2019-07-11 Ep4 inhibitors and synthesis thereof

Publications (1)

Publication Number Publication Date
CA3107023A1 true CA3107023A1 (en) 2020-01-16

Family

ID=69141735

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3107023A Pending CA3107023A1 (en) 2018-07-11 2019-07-11 Ep4 inhibitors and synthesis thereof

Country Status (7)

Country Link
US (2) US20210300921A1 (https=)
EP (1) EP3820469A4 (https=)
JP (1) JP2021530487A (https=)
CN (1) CN113301896A (https=)
CA (1) CA3107023A1 (https=)
IL (1) IL280051B2 (https=)
WO (1) WO2020014445A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10973834B2 (en) 2018-04-16 2021-04-13 Arrys Therapeutics, Inc. EP4 inhibitors and use thereof
US20210315909A1 (en) 2018-07-11 2021-10-14 Arrys Therapeutics, Inc. Polymorphic compounds and uses thereof
US11254675B2 (en) * 2019-08-12 2022-02-22 Cadila Healthcare Limited Process for preparation of grapiprant
CN110386941A (zh) * 2019-08-15 2019-10-29 上海邦耀生物科技有限公司 Ep4受体拮抗剂和pd-1抑制剂联合用于癌症的治疗
CN115697317A (zh) * 2020-04-08 2023-02-03 株式会社AskAt Ep4受体拮抗剂用于治疗肝癌、黑色素瘤、淋巴瘤和白血病的应用
TWI877433B (zh) * 2020-11-30 2025-03-21 大陸商杭州阿諾生物醫藥科技有限公司 用於治療ｐｉｋ３ｃａ突變癌症的組合療法
CN117377471A (zh) * 2021-05-28 2024-01-09 凯复(苏州)生物医药有限公司 治疗肿瘤的联合疗法
US20240343725A1 (en) * 2021-08-01 2024-10-17 Zenfold Sustainable Technologies Private Limited A process for the preparation of grapiprant and its intermediates
CN117466888A (zh) * 2023-10-30 2024-01-30 西北农林科技大学 一种1h-咪唑并[4,5-c]吡啶化合物的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN2001000224A (es) * 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
CN1867551B (zh) * 2003-09-03 2013-09-11 拉夸里亚创药株式会社 作为前列腺素e2拮抗剂的苯基或吡啶基酰胺化合物
EP1740211A2 (en) * 2004-04-20 2007-01-10 Pfizer Products Incorporated Combinations comprising alpha-2-delta ligands and ep4 receptor antagonists
CN101137656B (zh) * 2005-03-11 2010-12-22 拉夸里亚创药株式会社 咪唑衍生物的晶型
EP3431085B1 (en) * 2009-04-22 2023-10-11 AskAt Inc. Selective ep4 receptor antagonistic substance for treatment of cancer
UA115576C2 (uk) * 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4
NZ733234A (en) * 2014-03-06 2018-08-31 Aratana Therapeutics Inc Crystalline forms of grapiprant
US10342785B2 (en) * 2016-11-04 2019-07-09 Askat Inc. Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer

Also Published As

Publication number Publication date
US20240254120A1 (en) 2024-08-01
JP2021530487A (ja) 2021-11-11
IL280051A (en) 2021-03-01
US20210300921A1 (en) 2021-09-30
IL280051B1 (en) 2023-11-01
EP3820469A4 (en) 2022-04-13
CN113301896A (zh) 2021-08-24
EP3820469A1 (en) 2021-05-19
WO2020014445A1 (en) 2020-01-16
IL280051B2 (en) 2024-03-01

Similar Documents

Publication Publication Date Title
US12577208B2 (en) TEAD inhibitors and uses thereof
US20240254120A1 (en) Ep4 inhibitors and synthesis thereof
US11433137B2 (en) Compounds for treating cancer
JP2026027329A (ja) ネクチン－４に特異的な二環コンジュゲート及びその使用
US12295962B2 (en) Polymorphic compounds and uses thereof
KR20230172548A (ko) Mek 억제제 및 이의 용도
JP2023553866A (ja) Ｔｅａｄ阻害剤、及びその使用
WO2019204257A1 (en) Ep4 inhibitors and use thereof
US11878958B2 (en) MEK inhibitors and uses thereof
WO2023114984A1 (en) Tead inhibitors and uses thereof
WO2023173053A1 (en) Mek inhibitors and uses thereof
US20210353648A1 (en) Grapiprant unit dosage forms
KR20240119141A (ko) 암의 치료 방법
WO2023211889A1 (en) Polymorphic compounds and uses thereof

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260129